Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biotech company specializing in obesity and metabolic health disorders, has scheduled its Q2 2025 earnings call for August 7, 2025, at 1:30 p.m. PT/4:30 p.m. ET.
The company will release its financial results and business update after market close on the same day. Investors can access the live webcast, earnings release, financial tables, and presentation materials through Skye's Investor Relations website. A replay will be available following the call.
Skye Bioscience (Nasdaq: SKYE), un'azienda biotecnologica in fase clinica specializzata in obesità e disturbi metabolici, ha programmato la sua conference call sui risultati del secondo trimestre 2025 per il 7 agosto 2025 alle 13:30 PT / 16:30 ET.
La società pubblicherà i risultati finanziari e un aggiornamento aziendale dopo la chiusura del mercato nello stesso giorno. Gli investitori potranno accedere alla diretta web, al comunicato sugli utili, alle tabelle finanziarie e ai materiali della presentazione tramite il sito web delle Relazioni con gli Investitori di Skye. Una registrazione sarà disponibile dopo la chiamata.
Skye Bioscience (Nasdaq: SKYE), una empresa biotecnológica en etapa clínica especializada en obesidad y trastornos metabólicos, ha programado su llamada de resultados del segundo trimestre de 2025 para el 7 de agosto de 2025 a la 1:30 p.m. PT / 4:30 p.m. ET.
La compañía publicará sus resultados financieros y una actualización comercial después del cierre del mercado ese mismo día. Los inversores podrán acceder a la transmisión en vivo, el comunicado de resultados, las tablas financieras y los materiales de presentación a través del sitio web de Relaciones con Inversores de Skye. Una repetición estará disponible después de la llamada.
Skye Bioscience (나스닥: SKYE)는 비만 및 대사 질환을 전문으로 하는 임상 단계 바이오텍 회사로, 2025년 8월 7일 오후 1시 30분 PT / 오후 4시 30분 ET에 2025년 2분기 실적 발표 컨퍼런스 콜을 예정하고 있습니다.
회사는 같은 날 시장 마감 후 재무 결과 및 사업 업데이트를 발표할 예정입니다. 투자자들은 Skye 투자자 관계 웹사이트를 통해 생중계 웹캐스트, 실적 발표, 재무 표 및 프레젠테이션 자료에 접속할 수 있습니다. 콜 종료 후 다시보기 서비스도 제공됩니다.
Skye Bioscience (Nasdaq : SKYE), une société biotechnologique en phase clinique spécialisée dans l'obésité et les troubles métaboliques, a programmé sa conférence téléphonique sur les résultats du deuxième trimestre 2025 pour le 7 août 2025 à 13h30 PT / 16h30 ET.
La société publiera ses résultats financiers et une mise à jour commerciale après la clôture du marché le même jour. Les investisseurs pourront accéder au webinaire en direct, au communiqué de résultats, aux tableaux financiers et aux supports de présentation via le site Relations Investisseurs de Skye. Un replay sera disponible après l'appel.
Skye Bioscience (Nasdaq: SKYE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Adipositas und Stoffwechselerkrankungen spezialisiert hat, hat seine Telefonkonferenz zu den Ergebnissen des zweiten Quartals 2025 für den 7. August 2025 um 13:30 Uhr PT / 16:30 Uhr ET angesetzt.
Das Unternehmen wird am selben Tag nach Börsenschluss seine Finanzergebnisse und ein Geschäftsupdate veröffentlichen. Investoren können den Live-Webcast, die Ergebnisveröffentlichung, Finanztabellen und Präsentationsmaterialien über die Investor-Relations-Website von Skye abrufen. Eine Aufzeichnung wird nach dem Anruf verfügbar sein.
- None.
- None.
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day.
The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay will be available at the same website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FAQ
When will Skye Bioscience (SKYE) report Q2 2025 earnings?
How can investors access Skye Bioscience's (SKYE) Q2 2025 earnings call?
What time is Skye Bioscience's (SKYE) Q2 2025 earnings call?
What is Skye Bioscience's (SKYE) main business focus?
